Danaher Corporation
General ticker "DHR" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $148.9B (TTM average)
Danaher Corporation follows the US Stock Market performance with the rate: 50.8%.
Estimated limits based on current volatility of 1.1%: low 194.01$, high 198.41$
Factors to consider:
- Earnings expected soon, date: 2026-04-21 bmo
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-03-27, amount 0.40$ (Y0.82%)
- Total employees count: 63000 as of 2024
- China accounted for 11.7% of revenue in the fiscal year ended 2024-12-31
- US accounted for 41.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Economic downturns and volatility, Inflationary pressures, Interest rate fluctuations, Geopolitical risks, Supply chain disruptions
- Current price 15.4% below estimated low
- Earnings for 12 months up through Q4 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [216.34$, 293.72$]
- 2025-12-31 to 2026-12-31 estimated range: [230.20$, 310.15$]
Financial Metrics affecting the DHR estimates:
- Negative: with PPE of 30.7 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 20.37 > 18.52
- Positive: 0.07 < Operating cash flow per share per price, % of 3.98
- Positive: 1.88 < Return on assets ratio (scaled to [-100,100]) of 4.79
- Positive: Interest expense per share per price, % of 0.17 <= 0.73
- Negative: Industry earnings per price (median), % of 0 <= 0
- Positive: -4.45 < Investing cash flow per share per price, % of -1.18
- Negative: -0.75 < Inventory ratio change, % of -0.37
Short-term DHR quotes
Relationship graph
Long-term DHR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $26,643.00MM | $23,890.00MM | $23,875.00MM |
| Operating Expenses | $19,107.00MM | $18,688.00MM | $19,012.00MM |
| Operating Income | $7,536.00MM | $5,202.00MM | $4,863.00MM |
| Non-Operating Income | $-390.00MM | $-158.00MM | $-217.00MM |
| Interest Expense | $204.00MM | $286.00MM | $278.00MM |
| R&D Expense | $1,528.00MM | $1,503.00MM | $1,584.00MM |
| Income(Loss) | $7,146.00MM | $5,044.00MM | $4,646.00MM |
| Taxes | $818.00MM | $823.00MM | $747.00MM |
| Other Income(Loss) | $881.00MM | $543.00MM | $0.00MM |
| Profit(Loss)* | $8,090.00MM | $5,307.00MM | $3,899.00MM |
| Stockholders Equity | $50,082.00MM | $53,486.00MM | $49,543.00MM |
| Inventory | $2,765.00MM | $2,594.00MM | $2,330.00MM |
| Assets | $84,350.00MM | $84,488.00MM | $77,542.00MM |
| Operating Cash Flow | $8,519.00MM | $7,164.00MM | $6,688.00MM |
| Capital expenditure | $1,152.00MM | $1,383.00MM | $1,392.00MM |
| Investing Cash Flow | $-2,234.00MM | $-7,081.00MM | $-1,981.00MM |
| Financing Cash Flow | $-2,570.00MM | $-273.00MM | $-8,385.00MM |
| Earnings Per Share** | $11.16 | $7.21 | $5.33 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.